Net income · 2012–2025
Ultragenyx Pharmaceutical net income
−$575M−$6.0M · FY2025
Ultragenyx Pharmaceutical (RARE) reported −$575M in net income for fiscal 2025, −$6.0M from the year before.
| Fiscal year | Net income | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | −$575M | −$6.0M | Open → |
| FY20242024-12-31 | −$569M | +$38.0M | Open → |
| FY20232023-12-31 | −$607M | +$100M | Open → |
| FY20222022-12-31 | −$707M | −$253M | Open → |
| FY20212021-12-31 | −$454M | −$267M | Open → |
| FY20202020-12-31 | −$187M | +$216M | Open → |
| FY20192019-12-31 | −$403M | −$205M | Open → |
| FY20182018-12-31 | −$198M | +$105M | Open → |
| FY20172017-12-31 | −$302M | −$56.3M | Open → |
| FY20162016-12-31 | −$246M | −$100M | Open → |
| FY20152015-12-31 | −$146M | −$85.8M | Open → |
| FY20142014-12-31 | −$59.8M | −$24.7M | Open → |
| FY20132013-12-31 | −$35.1M | −$18.7M | Open → |
| FY20122012-12-31 | −$16.3M | — | Open → |
Net income — Net income is profit after tax and all expenses, as reported in the annual filing. Companies reporting a loss are excluded from this ranking.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Net income at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ultragenyx Pharmaceutical net income |url=https://companiesranked.com/en/company/ultragenyx-pharmaceutical/net-income |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ultragenyx Pharmaceutical net income. CompaniesRanked. https://companiesranked.com/en/company/ultragenyx-pharmaceutical/net-incomeBibTeX
@misc{companiesranked-en-company-ultragenyx-pharmaceutical-net-income-2026,
author = {{CompaniesRanked}},
title = {{Ultragenyx Pharmaceutical net income}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ultragenyx-pharmaceutical/net-income}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-057329 · February 18, 2026
{{cite web |title=Ultragenyx Pharmaceutical net income — 10-K (0001193125-26-057329) |url=https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-18}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.